LEADER 01929nam 2200361Ia 450 001 996386197403316 005 20200824121536.0 035 $a(CKB)1000000000617984 035 $a(EEBO)2248526829 035 $a(UnM)99896608e 035 $a(UnM)99896608 035 $a(EXLCZ)991000000000617984 100 $a19981119d1700 uy | 101 0 $aeng 135 $aurbn||||a|bb| 200 14$aThe famous, pleasant, and delightful history of Palladine of England$b[electronic resource] $eDiscoursing of honourable adventures, of knightly deeds of arms and chivalry: interlaced likewise with the love of sundry noble personages, as time and affection limited their desires. Herein is no offence offered to the wise by wanton speeches, or encouragement to the loose by lascivious matter. Translated out of French by A.M. one of the messengers of Her Majesties chamber 205 $aThe second edition. 210 $aLondon $cprinted by J. F. and sold by John Marshall, at the Bible in Gracechurch-street$d[1700?] 215 $a[8], 016 [i.e. 160] p. $cill. 300 $aPage 160 misnumbered 016. 300 $aA translation, by Anthony Munday, of part 1 of "L'histoire palladienne" by Claude Colet (1555), a version of the anonymous Spanish romance "Florando de Inglaterra" (1545). It has no connection with the Palmerin romances, with which it has been confused. See--Thomas, H. Bibliog. Soc. Trans., v. 13, p. 128. 300 $aRunning title reads: The pleasant history of Palladine of England. 300 $aReproduction of original in the Newberry Library. 330 $aeebo-0101 700 $aColet$b Claude$f16th cent.$01016595 701 $aMunday$b Anthony$f1553-1633.$0166411 801 0$bCu-RivES 801 1$bCu-RivES 801 2$bWaOLN 906 $aBOOK 912 $a996386197403316 996 $aThe famous, pleasant, and delightful history of Palladine of England$92420367 997 $aUNISA LEADER 03078nam 2200625 a 450 001 9910972624403321 005 20251017110056.0 010 $a0-309-22067-X 010 $a1-280-12334-6 010 $a9786613527202 010 $a0-309-22065-3 035 $a(CKB)2670000000176340 035 $a(OCoLC)794491570 035 $a(CaPaEBR)ebrary10554791 035 $a(SSID)ssj0000645747 035 $a(PQKBManifestationID)11380818 035 $a(PQKBTitleCode)TC0000645747 035 $a(PQKBWorkID)10683766 035 $a(PQKB)10169540 035 $a(MiAaPQ)EBC3378946 035 $a(Au-PeEL)EBL3378946 035 $a(CaPaEBR)ebr10554791 035 $a(CaONFJC)MIL352720 035 $a(OCoLC)785373830 035 $a(DNLM)1583262 035 $a(EXLCZ)992670000000176340 100 $a20120509d2012 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aFacilitating collaborations to develop combination investigational cancer therapies $eworkshop summary /$fMargie Patlak, Erin Balogh, and Sharyl J. Nass, rapporteurs ; Institute of Medicine of the National Academies 205 $a1st ed. 210 $aWashington, D.C. $cNational Academies Press$d2012 215 $a1 online resource (117 p.) 300 $a"National Cancer Policy Forum, Board on Health Care Services." 311 08$a0-309-22064-5 320 $aIncludes bibliographical references. 327 $aIntroduction -- Why Combinations and Collaborations Are Necessary -- Scientific Challenges in Developing Investigational Combination Therapies -- Overcoming Cultural Challenges to Collaborations Legal Issues in Collaborations -- Financial Challenges -- Regulatory Issues -- Codevelopment of Therapies for HIV as a Model -- Examples of Collaborations Relevant to Cancer -- Wrapping Up -- Appendix A: Examples of Collaborations -- Appendix B: Workshop Agenda -- References -- Acronyms. 330 $a"Advances in biomedical research have increased our understanding of the complex nature of disease and the interaction of multiple molecular pathways involved in cancer. Combining investigational products early in their development is thought to be a promising strategy for identifying effective therapies. The IOM's National Cancer Policy Forum held a workshop to discuss challenges and identify potential solutions to improve collaboration and advance the development of combination investigational cancer therapies."--Publisher's description. 606 $aCancer$xTreatment 615 0$aCancer$xTreatment. 701 $aPatlak$b Margie$01607028 701 $aBalogh$b Erin$01089066 701 $aNass$b Sharyl J$0857626 712 02$aNational Cancer Policy Forum (U.S.) 712 02$aInstitute of Medicine (U.S.).$bBoard on Health Care Services. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910972624403321 996 $aFacilitating collaborations to develop combination investigational cancer therapies$94446112 997 $aUNINA